Dysport vs Botox: the Unit Prices Are Not Comparable

A clinic quotes wrinkle injections by the unit. Botox Cosmetic runs about 10 to 25 dollars a unit in the United States, and Dysport about 4 to 8.¹ On that comparison Dysport is the cheap one, by a wide margin.

The comparison does not survive the labels. Every botulinum toxin approved in the United States carries a sentence saying its units mean nothing outside its own vial, and each label sets its own dose for the same frown lines. Botox Cosmetic says 20 units. Dysport says 50.²³

What the five labels actually say

Injections of this kind are the volume business of cosmetic medicine. Neuromodulator injections accounted for half of all minimally invasive treatments recorded by the American Society of Plastic Surgeons in 2025.⁴

There are five botulinum toxin type A products approved for glabellar lines in the United States, the vertical frown lines between the eyebrows. Each label carries two things that matter to a price comparison: a warning that its units are its own, and a fixed recommended dose.

Label doses as published on DailyMed, the National Library of Medicine's label service.²³⁵⁶⁷

The wording on non-interchangeability is not a general caution about brands. It is specific, and it names the reason.

Dysport's label states that "the potency Units of DYSPORT are specific to the preparation and assay method utilized" and that "they are not interchangeable with other preparations of botulinum toxin products".²

Botox Cosmetic's label is equally explicit. Its units "cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method".³ The Xeomin, Jeuveau and Daxxify labels carry the same restriction in their own words.⁵⁶⁷

A unit, in other words, is a measurement of biological activity in one manufacturer's assay. It is not a milligram and not a millilitre. Two brands can print the same number on a vial and mean different quantities of effect.

The arithmetic the price lists skip

Take the per-unit prices a clinic-operations guide published in September 2026 for patients in the United States, and multiply each by that brand's own label dose for frown lines.¹

Dysport at 4 to 8 dollars a unit, over 50 units, is 200 to 400 dollars. Botox Cosmetic at 10 to 25 dollars, over 20 units, is 200 to 500. Xeomin lands at 200 to 340, and Jeuveau at 240 to 300. The cheapest unit price in the group produces a treatment cost in the same band as the most expensive one.

Daxxify is the exception that proves the mechanism. It is priced highest per unit, at 15 to 25 dollars, and its label dose is 40 units rather than 20.⁷ Its frown-line treatment therefore works out at roughly 600 to 1,000 dollars, well above the others. The premium is not doubled by the price. It is doubled by the dose.

The gap widens once the treatment is more than one area. Botox Cosmetic's label sets 24 units for lateral canthal lines, the creases at the outer corner of the eye, across six sites.³ For forehead lines it specifies 40 units in total, 20 into the frontalis and 20 into the glabellar muscles, because the label will not license the forehead on its own. A three-area upper face on the label doses is therefore 64 units of Botox Cosmetic, not 60, and a patient quoted "per area" has no way to see that.

This publication did that multiplication. The unit prices are one industry source's ranges rather than a survey, and real quotes vary by city and injector, so the totals are a comparison of published ranges and not a measured market average.

The same guide tells its clinic-owner readers exactly this, in one line: the conversion means "the total treatment cost almost identical to other brands".¹ That sentence appears in trade material written for people selling the injections. It does not appear in the per-unit price a patient is quoted.

Where the 2.5-to-1 ratio comes from

Injectors do convert between brands, using a ratio of roughly 2.5 Dysport units to each Botox unit. The evidence behind that number is real, and it is worth knowing what it was measured on.

A double-blind randomised crossover trial enrolled 102 patients with cervical dystonia, a neurological condition causing involuntary neck contractions, and tested the 2.5-to-1 ratio directly.⁸ One 500-unit vial of Dysport was set against two 100-unit vials of Botox. The authors concluded that Dysport "was not inferior to Botox" in those patients "at a conversion factor of 2.5:1". Mean improvement slightly favoured Botox without reaching statistical significance.

A systematic literature review then pooled the conversion studies and found that a ratio "between 1:2.5 and 1:3.0 provides comparable safety and efficacy".⁹ At 1 to 4, the review reported excessive side effects. At 1 to 3, efficacy was similar or greater but adverse effects rose.

Both of those bodies of evidence come from movement disorders rather than cosmetic use. The largest aesthetic figure available is a retrospective review of 500 patients and 736 treatments by a single physician, which settled on 1 to 2.67 for facial work and reported drooping eyelids in 0.6 percent.¹⁰ A 2012 economic analysis of aesthetic use put the underlying problem plainly: no fixed dose conversion ratio exists between the formulations.¹¹

So the ratio is a clinical convention supported by trials in a different indication, not a conversion factor the manufacturers accept. The labels still forbid the arithmetic that injectors perform daily.

Abroad, the multiplication often cannot be done

The per-unit quote is at least a number. In the destinations patients fly to for cheaper injections, it frequently does not exist.

An Istanbul clinic publishes its prices by facial region: 100 euros for the forehead, 100 for frown lines, 100 for crow's feet, 120 for two areas and 150 for three.¹² It names four toxin brands it may use. No unit count and no per-unit price appears for any of them.

Those four brands do not share a unit system. Two of them are the same products under other names: Nabota is the Korean-made toxin sold in the United States as Jeuveau, and Bocouture is the European name for the Merz product sold there as Xeomin.⁶

A Seoul clinic goes the other way and says so explicitly: "In Korea, pricing is closer to per-unit."¹³ It publishes unit counts by area, 15 to 25 units for frown lines, alongside area prices of about 80 to 150 dollars. A patient can reconstruct the dose from that page. On the Istanbul page there is nothing to reconstruct it from.

Two brand names that patients search for are not in the American label database at all. A query against DailyMed's label service for "Innotox" returns no results, and so does one for "Botulax".¹⁴¹⁵ Both are Korean-made toxins, and neither has a US label, which means no American per-unit price for them can be checked against a label dose. The disease-control agency's own note about product bought "through large online marketplaces" describes how they reach patients anyway.¹⁶

Neither approach is dishonest. They are different pricing conventions, and only one of them lets a patient check what is being injected against a label.

What the quoted price leaves out

The average price everyone cites is not a unit price. The American Society of Plastic Surgeons puts the average cost of botulinum toxin injections at 435 dollars.¹⁷ That is an average per treatment, across brands, doses and areas. It cannot be divided by units to check a quote, and the society does not say whether it includes related expenses.

The longer-lasting claim is not on the label. Daxxify is sold on duration, and its label states no duration in months at all. It records only that subjects in the trials "were followed for at least 24 weeks after treatment" and left the study when both they and the investigator scored back at baseline.⁷ A patient paying the highest per-unit price in the group, at twice the unit count, is paying for a claim the prescribing information does not make.

Dilution is not on the price list either. The unit count is fixed by the label, but the volume it is dissolved in is not always the label's, and a heavily diluted vial spreads further. Neither an area price nor a unit price reveals which was used.

Who injects, and what is in the vial, sits outside the price entirely. The US Centers for Disease Control and Prevention recorded 17 cases of harm from counterfeit or mishandled botulinum toxin injections across nine states, with 13 people hospitalised.¹⁶ Some had received "injections with counterfeit products or products with unverified sources", bought "through large online marketplaces instead of through authorized suppliers".

A field report on seven of those women, all injected in non-medical settings, found at least four had received counterfeit product from unlicensed injectors.¹⁸ The agency's advice is blunt: "If in doubt, don't get the injection."

A cheaper unit can still be the cheaper treatment. Nothing above says Dysport costs more. It says the unit price cannot tell you, and that at the published ranges the totals overlap almost completely.

How to use these numbers at the consultation

Ask which brand, by name, before asking the price. The brand fixes the label dose, and the label dose is what turns a per-unit price into a treatment price.

Ask how many units are planned for each area, and write the number down. Then do the multiplication yourself: units times the per-unit price is the only figure comparable across two clinics.

If the quote is per area, ask for the brand and the unit count anyway. A clinic that cannot say how many units of which product it plans to inject has not quoted you a dose.

Ask to see the vial, unopened, and check the name on it against the brand you were quoted. This is the one check that addresses the counterfeit problem rather than the pricing one.

And treat a conversion between brands as a clinical decision rather than a discount. The ratio injectors use comes from trials in a neurological condition, and every label in the group says the units do not convert.